MISTICS
Markers of Inflammation after Simvastatin in Ischemic Cortical Stroke
|
Status:
Enrollment complete. Results presented in May 2004.
Purpose:
To study the safety and efficacy of Simvastatin in the acute phase of ischemic stroke.
Interventions:
Simvastatin
HMG-CoA reductase inhibitor; lowers cholesterol
|
Year Presented:
2004
Design:
Pilot, randomized, double-blind, multi-center clinical trial.
Inclusion Criteria
Patients presenting with acute ischemic stroke with cortical involvment between 3 and 12 hours of stroke onset. NIHSS scores between 6 and 20.
Patient Involvement:
Patients were randomized to receive either Simvastatin (n=28) or placebo (n=28) 40mg until day 7 and 20mg until day 90.
Primary Outcome:
Efficacy and neurological outcome at day 1, 3, 5, 7 and 90.
Results:
Patients receiveing Simvastatin improved significantly by day 3 (46.4% vs 17.9%, p<0.022) and had a greater improvement in NIHSS scores at day 90 (-9 points vs -5 points). The Simvastatin group had a higher proportion of patients with great improvement (decrease of more than 8 NIHSS points) at day 90 (10 vs 3, p<0.044) and a higher proportion of patients with dramatic improvement (decrease of 10 points) at day 90 (11 vs 4, p<0.035).
Source of Information:
Presented at 26th Internation Stroke Conference (Feb 2001). Presented at 12th European Stroke Conference (May 2003).
|
|
Web Links and Publications:
|
|
This information last updated on: 8/14/2008
Reviewed on: 08/14/2008.
|
